Jade Biosciences

Jade Biosciences

Yahoo Finance • 11 days ago

Is Jade Biosciences, Inc. (JBIO) Stock a Rising Biotech Opportunity in the $20B IgA Nephropathy Market?

We recently compiled a list of the 10 Best Biotech Stocks to Buy According to Analysts. Jade Biosciences, Inc. (NASDAQ:JBIO) is one of the best biotech stocks on this list. TheFly reported on June 15 that UBS initiated coverage of JBIO wi... Full story

Yahoo Finance • 18 days ago

Top Biotech Gainers: BOLD Begins Anew, MNPR NDA Filing On Track, GALT Soars On FDA Alignment

(RTTNews) - Today's top gainers include Boundless Bio, which is combining with privately held Serapha; Monopar, on track for an NDA submission of ALXN1840 for Wilson disease; Jade Biosciences, advancing its autoimmune disease pipeline; and... Full story

Yahoo Finance • last month

Jade Biosciences Announces Pricing of Public Offering of Common Stock

SAN FRANCISCO and VANCOUVER, British Columbia, June 03, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for au... Full story

Yahoo Finance • last month

Pre Market Movers: GNTA, HCWC, ZCMD Set The Path

(RTTNews) - Biotech companies are seeing significant pre-market activity this Monday, suggesting potential breakout opportunities. Assessing sentiment and momentum in the premarket sets the tone for a trader's day. In the Green - Premark... Full story

Yahoo Finance • last month

Jade Biosciences to Host Conference Call and Webcast on June 1, 2026, at 8:00 a.m. ET to Discuss Interim Phase 1 Healthy Volunteer Results for JADE101, a Novel, Potentially Best-in-Class Anti-APRIL Monoclonal Antibody in Development for IgA Nephropathy

SAN FRANCISCO and VANCOUVER, British Columbia, May 29, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (the “Company” or “Jade”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for aut... Full story

Yahoo Finance • 2 months ago

Jade Biosciences Announces First Participant Dosed in First-in-Human Phase 1 Clinical Trial of JADE201, a Novel Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody

Interim Phase 1 data in rheumatoid arthritis expected in 2027 are anticipated to inform indication prioritization across multiple potential autoimmune indications supported by BAFF-R biology JADE201 preclinical data demonstrated dose-depen... Full story

Yahoo Finance • 2 months ago

Why This Biotech Fund Added $7 Million to an Oncology Stock Up 120%

Key Points Avidity Partners added 259,700 shares of Enliven Therapeutics in the first quarter; the estimated transaction value was $7.19 million (based on quarterly average pricing). The quarter-end position value increased by $14.33 mill... Full story

Yahoo Finance • 4 months ago

Jade Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

JADE101 Phase 1 healthy volunteer interim data expected in the second quarter of 2026; Phase 2 clinical trial in patients with IgA nephropathy expected to begin mid-2026 with preliminary data anticipated in 2027JADE201, a half-life extende... Full story

Yahoo Finance • 7 months ago

Jade Biosciences Announces $45 Million Private Placement

SAN FRANCISCO and VANCOUVER, British Columbia, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“the Company” or “Jade”), (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for a... Full story

Yahoo Finance • 8 months ago

Jade Biosciences, Inc. GAAP EPS of -$0.48 beats by $0.19

* Jade Biosciences, Inc. press release [https://seekingalpha.com/pr/20307339-jade-biosciences-reports-third-quarter-2025-financial-results-and-provides-corporate-update] (JBIO [https://seekingalpha.com/symbol/JBIO]): Q3 GAAP EPS of -$0.4... Full story

Yahoo Finance • 8 months ago

Jade Biosciences Presents New Data Demonstrating a Favorable Preclinical Safety Profile of JADE101 and a Translational Analysis of APRIL Mediated Biomarker Responses at the American Society of Nephrology Kidney Week 2025

SAN FRANCISCO and VANCOUVER, British Columbia, Nov. 08, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“the Company” or “Jade”), (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for a... Full story

Yahoo Finance • 8 months ago

Jade Biosciences to Participate in Upcoming Conferences

SAN FRANCISCO and VANCOUVER, British Columbia, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”), (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announ... Full story

Yahoo Finance • 9 months ago

Jade Biosciences Announces New Data Presentations for JADE101 at the American Society of Nephrology Kidney Week 2025

Presentations to highlight JADE101’s preclinical safety profile and translational framework guiding its clinical development in IgA nephropathy JADE101 is an investigational, potentially best-in-class disease-modifying anti-APRIL monoclona... Full story

Yahoo Finance • 9 months ago

Jade Biosciences offers $135 million equity through private placement

* Jade Biosciences (NASDAQ:JBIO [https://seekingalpha.com/symbol/JBIO]) has entered into a private placement resulting in gross proceeds of approximately $135 million to the Company. * The company is selling an aggregate of (i) 13,368,... Full story

Yahoo Finance • 9 months ago

Jade Biosciences Announces JADE201, a Potentially Best-in-Class Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody in Development for Autoimmune Diseases

JADE201 builds on clinical proof-of-concept for BAFF-R targeting, adding half-life extension technology to provide extended receptor occupancy with the goal of delivering deeper, more durable B cell depletion with less frequent subcutaneou... Full story

Yahoo Finance • 9 months ago

Jade Biosciences Announces $135 Million Private Placement

SAN FRANCISCO and VANCOUVER, British Columbia, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“the Company” or “Jade”), (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for a... Full story

Yahoo Finance • 10 months ago

Jade Biosciences Announces First Cohort Dosed in Phase 1 Healthy Volunteer Clinical Trial of JADE101, a Novel and Potentially Best-in-Class Anti-APRIL Monoclonal Antibody Being Evaluated for the Treatment of IgA Nephropathy

Selective APRIL inhibition has shown disease-modifying potential in IgAN patient clinical trialsJADE101 has shown ultra-high binding affinity and a differentiated pharmacokinetic and pharmacodynamic profile preclinically, supporting the po... Full story

Yahoo Finance • 11 months ago

Jade Biosciences Posts Wider Loss in Q2

Key Points Jade Biosciences reported a net loss per share of $0.86 (GAAP) for Q2 2025. The company missed analyst GAAP EPS estimates by $0.43, with the net loss per share widening significantly year over year. Research and development spe... Full story

Yahoo Finance • 11 months ago

Jade Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Presented preclinical data for JADE101 at the 62nd European Renal Association Congress, highlighting its potential as a best-in-class anti-APRIL monoclonal antibody for IgA nephropathy Phase 1 healthy-volunteer study of JADE101 expected to... Full story

Yahoo Finance • 12 months ago

Jefferies initiates Jade Biosciences stock with Buy rating on IgAN treatment

Investing.com - Jefferies initiated coverage on Jade Biosciences (NASDAQ:JBIO), currently trading at $9.82 with a market cap of $317 million, with a Buy rating and a $16.00 price target on Monday. According to InvestingPro data, analysts’... Full story